2. Signaling Pathways
  3. PI3K/Akt/mTOR
  4. PI3K
  5. PI3KC2β Isoform

PI3KC2β

PI3KC2β is a class II phosphoinositide 3-kinase that regulates lipid signaling, vesicular trafficking, cytoskeletal organization, cell migration, and cell survival[1]. Mechanistically, PI3KC2β links phosphoinositide metabolism to endosomal trafficking because PI3KC2β loss in human cerebral microvascular endothelial cells increases Rab11-dependent VE-cadherin recycling and stabilizes endothelial cell-cell junctions[2]. In disease models, inactive PI3KC2β protects mice against vascular permeability, edema, cerebral infarction, and inflammatory response after ischemic stroke[2]. PI3KC2β also limits endothelial mTORC1 signaling during angiogenic growth, and kinase-inactive PI3KC2β causes enlarged blood vessels through increased endothelial cell size rather than increased proliferation or migration[3]. In MTM1-related myotubular myopathy models, PI3KC2β inhibition improves muscle function and survival, while selective kinase inactivation prevents muscle atrophy, weakness, histopathology, sarcomere defects, and triad disorganization in Mtm1-knockout mice[4][5]. Compared with related isoforms, PI3KC2β differs from PI3KC2α because PI3KC2α deficiency increases vascular permeability, whereas PI3KC2β inactivation preserves vascular integrity after injury[2]. For experimental applications, kinase-dead PI3KC2β models support target validation, but no specific PI3KC2β kinase inhibitor has been developed and published[5].

PI3KC2β Related Products (13):

Cat. No. Product Name Effect Purity
  • HY-10115
    PI-103
    		Inhibitor 99.82%
    PI-103 is a potent PI3K and mTOR inhibitor with IC50s of 8 nM, 88 nM, 48 nM, 150 nM, 20 nM, and 83 nM for p110α, p110β, p110δ, p110γ, mTORC1, and mTORC2. PI-103 also inhibits DNA-PK with an IC50 of 2 nM. PI-103 induces autophagy.
  • HY-12030
    PIK-90
    		Inhibitor 99.70%
    PIK-90 is a DNA-PK and PI3K inhibitor, which inhibits p110α, p110γ and DNA-PK with IC50s of 11, 18 and 13 nM, respectively.
  • HY-12046
    PIK-93
    		Inhibitor 99.81%
    PIK-93 is the first potent, synthetic PI4K (PI4KIIIβ) inhibitor with IC50 of 19 nM, and also inhibits PI3Kγ and PI3Kα with IC50 of 16 nM and 39 nM, respectively.
  • HY-10344
    AZD 6482
    		Inhibitor 99.93%
    AZD 6482 (KIN-193) is a potent and selective p110β inhibitor with an IC50 of 0.69 nM.
  • HY-107834
    PIK-75
    		Inhibitor 99.94%
    PIK-75 is a reversible DNA-PK and p110α-selective inhibitor, which inhibits DNA-PK, p110α and p110γ with IC50s of 2, 5.8 and 76 nM, respectively. PIK-75 inhibits p110α >200-fold more potently than p110β (IC50=1.3 μM). PIK-75 induces apoptosis.
  • HY-118903
    PIK-124
    		Inhibitor
    PIK-124 is a thiazolidinone-based PI3Kγ-biased PI3K inhibitor, with an IC50 of 3 nM against PI3Kγ. PIK-124 exhibits cross-reactivity with PI3Kα (IC50 = 23 nM), PI3Kδ (IC50 = 340 nM), PI3KC2α (IC50 = 140 nM) and PI3KC2β (IC50 = 370 nM). PIK-124 is applicable to breast cancer-related research.
  • HY-13281
    PIK-75 hydrochloride
    		Inhibitor 99.66%
    PIK-75 hydrochloride is a reversible DNA-PK and p110α-selective inhibitor, which inhibits DNA-PK, p110α and p110γ with IC50s of 2, 5.8 and 76 nM, respectively. PIK-75 hydrochloride inhibits p110α >200-fold more potently than p110β (IC50=1.3 μM). PIK-75 hydrochloride induces apoptosis.
  • HY-156371
    MIPS-21335
    		Inhibitor 99.61%
    MIPS-21335 is a PI3KC2α inhibitor with an IC50 of 7 nM. MIPS-21335 also inhibits PI3KC2β, p110α, p110β and p110δ, with IC50 values of 43, 140, 386 and 742 nM, respectively. MIPS-21335 has antithrombotic effect. MIPS-21335 can be used for the researches of cardiovascular disease and metabolic disease, such as thrombosis and hyperlipidemia.
  • HY-15466
    Izorlisib
    		Inhibitor 99.01%
    Izorlisib (CH5132799) is a selective class I PI3K inhibitor. Izorlisib inhibits class I PI3Ks, particularly PI3Kα, with an IC50 of 14 nM.
  • HY-112443
    AZD3458
    		Inhibitor 99.71%
    AZD3458 is a potent and remarkably selective PI3Kγ inhibitor with pIC50s of 9.1, 5.1, <4.5, and 6.5 for PI3Kγ, PI3Kα, PI3Kβ, and PI3Kδ, respectively.
  • HY-107365
    PQR530
    		Inhibitor 99.98%
    PQR530 is a potent, ATP-competitive, orally bioavailable and brain-penetrant dual pan-PI3K/mTORC1/2 inhibitor, with a subnanomolar Kd toward PI3Kα and mTOR (0.84 and 0.33 nM, respectively). Antitumor activity.
  • HY-13261
    A66
    		Inhibitor 99.73%
    A66 is a highly specific and selective p110α inhibitor with an IC50 of 32 nM.
  • HY-112608
    CHMFL-PI3KD-317
    		Inhibitor 98.04%
    CHMFL-PI3KD-317 is a highly potent, selective and orally active PI3Kδ inhibitor, with an IC50 of 6 nM, and exhibits over 10-1500 fold selectivity over other class I, II and III PIKK family isoforms, such as PI3Kα (IC50, 62.6 nM), PI3Kβ (IC50, 284 nM), PI3Kγ (IC50, 202.7 nM), PIK3C2A (IC50, >10000 nM), PIK3C2B (IC50, 882.3 nM), VPS34 (IC50, 1801.7 nM), PI4KIIIA (IC50, 574.1 nM) and PI4KIIIB (IC50, 300.2 nM). CHMFL-PI3KD-317 inhibits PI3Kδ-mediated Akt T308 phosphorylation in Raji cells, with an EC50 of 4.3 nM. CHMFL-PI3KD-317 has antiproliferative effects on cancer cells.